A new study adds to the existing body of evidence that suggests nasal sprays can bolster your defences against coronavirus. The study in question deployed the Taffix spray, but as Dr Chris explained on This Morning, a hay fever nasal spray can deliver the same results. “Nasal sprays that protect against hay fever work the same way but can do the same against viruses and bacteria,” he said.
As Dr Chris explained to Holly and Phil, nasal sprays contain powder, the powder coats the lining of the nose and with the moisture inside the nose it forms of a protective gel.
This forms a barrier that prevents the virus from getting into the body, he said.
The renewer interest in nasal sprays comes after a Taffic, Israeli-made nasal spray appears to have contributed to a reduced infection rate among worshippers celebrating Jewish new year.
Of 83 worshipers who used the spray as instructed before Rosh Hashanah prayers and for the following two weeks, just two contracted coronavirus.
READ MORE: Nigerian variant found in UK could be resistant to vaccines – symptoms to spot
The study was conducted by makers of the Taffix spray, Nasus Pharma, along with scientists from the University of Haifa, the University of Virginia, and the Hadassah Medical Center in Jerusalem.
According to the study, Nasus Pharma approached a medium-sized synagogue community of some 250 members in Bnei Brak ahead of Rosh Hashanah in September 2020 to gauge their interest in participating in the trial involving the spray, which was advertised as an extra layer of protection.
Each member was eligible to collect a bottle of Taffix at the synagogue the day before Rosh Hashana prayers and received written instructions on the proper usage of the spray.
The drive to find novel approaches stemmed from the higher than average infection rate among ultra-orthodox communities at the time.
How to live longer: Best time of the day to exercise [INSIGHT]
Apple cider vinegar benefits: Suprising health benefits [TIPS]
Hair loss treatment: Rosemary oil shown to help [ADVICE]
At the end of the two-week trial, 81 of the 83 members of the synagogue who used the spray as instructed — every five hours whenever they left their residences for the following 14 days — did not contract the virus.
The two who did get infected rarely used the spray, and the remaining members of the community did not use Taffix at all.
“These important results conform with prior in vitro studies performed with Taffix™ that proved its robust activity against the transmission of SARS-CoV-2 ,” said Nasus Pharma CEO Dr Dalia Megiddo.
“This is the first clinical real-life data showing that the use of Taffix is highly effective even in the worst-case scenario of a super spread event in the heart of the worst-hit city in Israel.”